Prevention of hepatitis B virus recurrence after liver transplantation

Clinical Transplantation

Volumn 20, Issue SUPPL. 17, 2006, Pages 111-116

  Eisenbach, Christoph ^a   Sauer, Peter ^a   Mehrabi, Arianeb ^a   Stremmel, Wolfgang ^a   Encke, Jens ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adefovir; Hepatitis B; Hepatitis B immunoglobulin; Immunoprophylaxis; Lamivudine; Liver transplantation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ASPARTIC ACID; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; METHIONINE; NUCLEOSIDE ANALOG; PEGINTERFERON; TENOFOVIR; TYROSINE;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION; STANDARD; TREATMENT CONTRAINDICATION; VACCINATION; VIRUS MUTANT; VIRUS RESISTANCE;

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33750699268     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00609.x     Document Type: Article

References (79)

1. de Jongh FE, Janssen HL, deMan RA et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992: 103: 1630.
2. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992: 14: 104.
3. Todo S, Demetris AJ, Van T hiel D et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991: 13: 619.
4. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. Hepatology 2000: 32: 1189.
5. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004: 24 (Suppl. 1): 55.
6. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002: 35: 1528.
7. Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology 1990: 12: 364.
8. Feray C, Zignego AL, Samuel D et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990: 49: 1155.
9. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005: 11: 402.
10. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993: 329: 1842.
11. Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997: 113: 1668.
12. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002: 8: S82.
13. Abdelmalek MF, Pasha TM, Zein NN et al. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003: 9: 1253.
14. Tur -Kaspa R, Shaul Y, Moore DD et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988: 167: 630.
15. Mc Millan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995: 22: 36.
16. G irlanda R, M ohsen AH, S mith H et al. Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. Liver Transpl 2004: 10: 58.
17. Ben-Ari Z, Ashur Y, Daudi N et al. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant 2004: 18: 415.
18. Marcellin P, Samuel D, Areias J et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994: 19: 6.
19. Tchervenkov JI, Tector AJ, Barkun JS et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997: 226: 356.
20. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993: 104: 1116.
21. Villeneuve JP, Condreay LD, Willems B et ]al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000: 31: 207.
22. Kapoor D, Guptan RC, Wakil SM et ]al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000: 33: 308.
23. Kitay-C ohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis. Transplantation 2000: 69: 2382.
24. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000: 33: 301.
25. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001: 33: 424.
26. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001: 34: 411.
27. Andreone P, Biselli M, Gramenzi A et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation 2002: 74: 1119.
28. Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Intern Med 2003: 253: 544.
29. Fontana RJ, Keeffe EB, Carey W et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002: 8: 433.
30. Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002: 123: 719.
31. Tillmann HL, Hadem J, Leifeld L et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006: 13: 256.
32. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001: 33: 751.
33. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996: 24: 711.
34. Merle P, Trepo C. Therapeutic management of hepatitis B-related cirrhosis. J Viral Hepat 2001: 8: 391.
35. Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001: 34: 895.
36. Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004: 126: 91.
37. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003: 38: 1419.
38. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003: 125: 292.
39. Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003: 39: 1085.
40. Van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003: 124: 586.
41. Honkoop P, De Man RA. Entecavir: A potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003: 12: 683.
42. Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005: 129: 1198.
43. Schilling R, Ijaz S, Davidoff M et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003: 77: 8882.
44. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996: 24: 1327.
45. Muller R, Gubernatis G, Farle M et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991: 13: 90.
46. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991: 337: 813.
47. Rimoldi P, Belli LS, Rondinara GF et al. Recurrent HBV/HDV infections under different immunoprophylaxis protocols. Transplant Proc 1993: 25: 2675.
48. Mc Gory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996: 61: 1358.
49. Konig V, Hopf U, Neuhaus P et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994: 58: 553.
50. Sawyer RG, Mc Gory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998: 227: 841.
51. Carman WF, Trautwein C, van Deursen FJ et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996: 24: 489.
52. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998: 27: 213.
53. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998: 27: 254.
54. Hawkins AE, Gilson RJ, Gilbert N et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996: 24: 8.
55. Trautwein C, Schrem H, Tillmann HL et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 1996: 24: 482.
56. Han SH, Martin P, Edelstein M et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003: 9: 182.
57. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999: 5: 491.
58. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003: 17: 254.
59. Lowell JA, Burgess S, Shenoy S, Peters M, Howard TK. Mercury poisoning associated with hepatitis-B immunoglobulin. Lancet 1996: 347: 480.
60. Lo CM, Cheung ST, Lai CL et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001: 233: 276.
61. Mutimer D, Pillay D, Dragon E et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999: 30: 715.
62. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996: 348: 1212.
63. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 2000: 70: 809.
64. Dodson SF, de Vera ME, Bonham CA et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000: 6: 434.
65. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998: 28: 585.
66. Yoshida EM, Erb SR, Partovi N et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999: 5: 520.
67. Marzano A, Salizzoni M, Debernardi-V enon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001: 34: 903.
68. Angus PW, Mc Caughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000: 6: 429.
69. Roche B, Feray C, Gigou M et al. HBV DNA persistence 10years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003: 38: 86.
70. Mc Caughan GW, Spencer J, Koorey D et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999: 5: 512.
71. Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000: 6: 741.
72. Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003: 38: 811.
73. Naoumov NV, Lopes AR, Burra P et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001: 34: 888.
74. Sanchez-Fueyo A, Martinez-Bauer E, Rimola A. Hepatitis B vaccination after liver transplantation. Hepatology 2002: 36: 257.
75. Sanchez-Fueyo A, Rimola A, Grande L et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000: 31: 496.
76. Bienzle U, Gunther M, Neuhaus R et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003: 38: 811.
77. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004: 126: 81.
78. Marzano A, Lampertico P, Mazzaferro V et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005: 11: 532.
79. Lo CM, Liu CL, Lau GK et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005: 11: 807.